Incyte Corporation
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- William J. Meury
- Full Time Employees
- 2,844
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 1801 Augustine Cut-Off Wilmington DE United States of America 19803
- IPO Date
- Nov 4, 1993
- CIK
- 0000879169
- Website
- incyte.com
- Similar Companies
- Business
- Incyte Corporation (INCY) is a Wilmington, Delaware-based biopharmaceutical company founded in 2002 that discovers, develops, and commercializes proprietary medicines for oncology, inflammation, autoimmunity, and dermatology; it operates globally in North America, Europe, and Asia with over 2,500 employees focused on unmet medical needs. The company markets a diversified portfolio of approved products including Jakafi (ruxolitinib) for myelofibrosis, polycythemia vera, and graft-versus-host disease; Opzelura (ruxolitinib) cream for atopic dermatitis and vitiligo; Pemazyre (pemigatinib) for cholangiocarcinoma and myeloid/lymphoid neoplasms; Monjuvi (tafasitamab-cxix) for relapsed or refractory diffuse large B-cell lymphoma; Tabrecta (capmatinib) for non-small cell lung cancer; Iclusig (ponatinib) for leukemia; and Olumiant (baricitinib) for rheumatoid arthritis and alopecia areata; it also advances a robust pipeline of clinical candidates discovered in-house targeting immunology, hematology-oncology, and inflammatory skin conditions. Recent developments include the 2024 acquisition of Escient Pharmaceuticals for $750 million to add first-in-class oral MRGPRX2 antagonists EP262 for hidradenitis suppurativa, prurigo nodularis, and other pruritic skin diseases and EP547 for pruritus in kidney and liver diseases; FDA approval of Niktimvo (axatilimab-csfr) with partner Syndax Pharmaceuticals in August 2024 for chronic graft-versus-host disease; relocation of over 300 Pennsylvania jobs to expanded downtown Wilmington headquarters by 2026 supporting more than 500 positions; and a 2025 roadmap featuring four potential product launches such as ruxolitinib XR and povorcitinib expansions, four pivotal trial readouts, seven proof-of-concept disclosures, and at least three Phase 3 initiations toward over 10 high-impact launches by 2030.
Here's Why Incyte (INCY) is a Strong Momentum Stock
Here's Why Incyte (INCY) is a Strong Growth Stock
Opzelura® (ruxolitinib) Cream Becomes First Steroid-Free Topical JAK Inhibitor Approved in the European Union for Adults with Moderate Atopic Dermatitis
INCY Q2 Earnings & Revenues Beat on Higher Sales, '26 View Raised
Incyte Corporation (INCY) Q2 2026 Earnings Call Transcript
Here's Why Incyte (INCY) is a Strong Value Stock
Compared to Estimates, Incyte (INCY) Q2 Earnings: A Look at Key Metrics
Incyte Q2 Earnings Call Highlights
Incyte: From Buy To Hold After A 93% Rally (Rating Downgrade)
Incyte (INCY) Q2 Earnings and Revenues Top Estimates
Incyte lifts annual revenue forecast after settlement with CMS
ServiceNow, Meta, eBay And A Health Care Stock On CNBC's ‘Final Trades'
Incyte Reports Second Quarter 2026 Financial Results and Provides Business Updates
Entropy Technologies LP Grows Stock Holdings in Incyte Corporation $INCY
Dai ichi Life Insurance Company Ltd Boosts Stake in Incyte Corporation $INCY
Incyte Gears Up to Report Q2 Earnings: Is a Beat Around the Corner?
HALO Inks Deal With INCY to Support Cancer Therapy Development
Incyte (INCY) Reports Next Week: Wall Street Expects Earnings Growth
Bank of New York Mellon Corp Trims Stock Position in Incyte Corporation $INCY
Fifth Third Bancorp Boosts Stock Position in Incyte Corporation $INCY